What is the share price of Alivus Life Sciences Ltd (ALIVUS) today?
The share price of ALIVUS as on 9th May 2025 is ₹1115.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alivus Life Sciences Ltd (ALIVUS) share?
The past returns of Alivus Life Sciences Ltd (ALIVUS) share are- Past 1 week: 1.08%
- Past 1 month: 11.52%
- Past 3 months: -9.15%
- Past 6 months: 2.25%
- Past 1 year: 33.87%
- Past 3 years: 148.52%
- Past 5 years: 49.04%
What are the peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS)?
The peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS) include:What is the dividend yield % of Alivus Life Sciences Ltd (ALIVUS) share?
The current dividend yield of Alivus Life Sciences Ltd (ALIVUS) is 2.02.What is the market cap of Alivus Life Sciences Ltd (ALIVUS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd (ALIVUS) is ₹13680.51 Cr as of 9th May 2025.What is the 52 week high and low of Alivus Life Sciences Ltd (ALIVUS) share?
The 52-week high of Alivus Life Sciences Ltd (ALIVUS) is ₹1335.10 and the 52-week low is ₹755.95.What is the PE and PB ratio of Alivus Life Sciences Ltd (ALIVUS) stock?
The P/E (price-to-earnings) ratio of Alivus Life Sciences Ltd (ALIVUS) is 29.05. The P/B (price-to-book) ratio is 5.87.Which sector does Alivus Life Sciences Ltd (ALIVUS) belong to?
Alivus Life Sciences Ltd (ALIVUS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alivus Life Sciences Ltd (ALIVUS) shares?
You can directly buy Alivus Life Sciences Ltd (ALIVUS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alivus Life Sciences Ltd
ALIVUS Share Price
1,115.600.86% (+9.50)
ALIVUS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
ALIVUS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.97 | 5.87 | 2.02% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 48.32 | 6.28 | 0.53% |
ALIVUS Analyst Ratings & Forecast
Detailed Forecast 80%
Analysts have suggested that investors can buy this stock
from 5 analysts
Price Upside
Earnings Growth
Rev. Growth
ALIVUS Company Profile
Alivus Life Sciences Ltd develops and manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services for chronic therapeutic areas.
Investor Presentation
View olderALIVUS Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
43.72
1Y Return
16.74%
Buy Reco %
88.24
CIPLA
PE Ratio
29.00
1Y Return
8.92%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
64.18
1Y Return
24.44%
Buy Reco %
68.00
MANKIND
PE Ratio
51.94
1Y Return
10.91%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.01
1Y Return
1.66%
Buy Reco %
46.67
ALIVUS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ALIVUS Stock Summary · August 2024
In its Q1 FY'25 earnings call, the company showcased a robust performance with a 9.7% revenue increase, driven by strong demand in the Generic API segment and a nearly 10% sequential growth overall. Despite facing operational challenges, including air freight disruptions and regulatory compliance issues, management remains optimistic about future growth, particularly in the CDMO sector, where new projects are expected to significantly boost revenue. The strategic focus on expanding the product pipeline, coupled with a commitment to environmental compliance, positions the company favorably in a competitive market. While margins have been impacted by a shift in product mix, there is confidence in maintaining profitability through effective cost management and strong customer relationships. Overall, the outlook remains positive, with plans for continued investment in capacity and innovation to meet rising demand.
Key Points on Alivus Stock
ALIVUS Stock Growth Drivers
8Strong Financial Performance
Glenmark Life Sciences reported a revenue of INR 588 crores in Q1 FY '25, reflecting
Resilient Business Operations
The company demonstrated resilience with broad-based growth across various geographies, particularly in the GPL business,
ALIVUS Stock Challenges
5Regulatory Compliance Issues
The company is currently facing a closure notice from the Gujarat Pollution Control Board due
Declining Gross Margins
The company reported a decline in gross margins, which fell to 51.1% from 55.5% in
ALIVUS Forecasts
Price
Revenue
Earnings
ALIVUS Share Price Forecast
2025
Current
₹1,115.60
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,115.60
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS Company Revenue Forecast
2024
Current
₹2.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹2.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ALIVUS Stock EPS (Earnings Per Share) Forecast
2024
Current
₹38.43
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹38.43
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS
Income
Balance Sheet
Cash Flow
Annual Normal View
ALIVUS Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.25 | 886.86 | 1,549.30 | 1,885.98 | 2,137.91 | 2,190.18 | 2,295.25 | 2,301.55 | ||||||||
Raw Materials | 0.04 | 633.56 | 668.66 | 948.17 | 977.96 | 1,068.56 | 1,025.21 | 1,648.34 | ||||||||
| Power & Fuel Cost | 0.00 | 57.81 | 76.75 | 74.19 | 100.92 | 115.60 | 112.46 | |||||||||
| Employee Cost | 0.15 | 106.28 | 142.28 | 149.13 | 168.72 | 180.18 | 258.16 | |||||||||
| Selling & Administrative Expenses | 0.00 | 44.20 | 42.05 | 48.50 | 48.64 | 65.47 | 64.12 | |||||||||
| Operating & Other expenses | 0.08 | -203.15 | 135.61 | 74.11 | 210.91 | 89.11 | 149.02 | |||||||||
EBITDA | -0.02 | 248.16 | 483.95 | 591.88 | 630.76 | 671.26 | 686.28 | 653.21 | ||||||||
| Depreciation/Amortization | 0.00 | 19.26 | 29.37 | 33.39 | 37.88 | 42.09 | 53.45 | 59.17 | ||||||||
| PBIT | -0.02 | 228.90 | 454.58 | 558.49 | 592.88 | 629.17 | 632.83 | 594.04 | ||||||||
| Interest & Other Items | 0.00 | 0.61 | 33.52 | 87.55 | 27.96 | 0.55 | 1.55 | 1.51 | ||||||||
| PBT | -0.02 | 228.29 | 421.06 | 470.94 | 564.92 | 628.62 | 631.28 | 592.53 | ||||||||
| Taxes & Other Items | 0.42 | 32.71 | 107.97 | 119.37 | 146.20 | 161.65 | 160.40 | 150.83 | ||||||||
| Net Income | -0.44 | 195.58 | 313.09 | 351.57 | 418.72 | 466.97 | 470.88 | 441.70 | ||||||||
| EPS | -8.00 | 36.10 | 29.04 | 32.61 | 36.36 | 38.11 | 38.43 | 36.05 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 42.00 | 22.50 | 0.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | 1.10 | 0.59 | 0.00 |
ALIVUS Company Updates
FY 2025
Investor Presentation
Jan 23PDF
Oct 24PDF
ALIVUS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alivus Life Sciences Ltd | 29.05 | 5.87 | 2.02% |
| Sun Pharmaceutical Industries Ltd | 43.72 | 6.24 | 0.77% |
| Cipla Ltd | 29.00 | 4.46 | 0.88% |
| Torrent Pharmaceuticals Ltd | 64.18 | 15.51 | 0.89% |
ALIVUS Stock Price Comparison
Compare ALIVUS with any stock or ETFCompare ALIVUS with any stock or ETF
ALIVUS
ALIVUS Shareholdings
ALIVUS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALIVUS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALIVUS Shareholding Pattern
ALIVUS Shareholding History
Foreign Institutions
Mutual Funds Invested in ALIVUS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alivus Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8782% | Percentage of the fund’s portfolio invested in the stock 1.71% | Change in the portfolio weight of the stock over the last 3 months 0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/52 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8708% | Percentage of the fund’s portfolio invested in the stock 0.45% | Change in the portfolio weight of the stock over the last 3 months 0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 53/103 (-13) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5067% | Percentage of the fund’s portfolio invested in the stock 0.74% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/64 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ALIVUS stock
Looks like this stock is not in any smallcase yet.
ALIVUS Events
ALIVUS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ALIVUS Upcoming Dividends
No upcoming dividends are available
ALIVUS Past Dividends
Cash Dividend
Ex DateEx DateOct 17, 2023
Interim
Interim | Div/Share: ₹22.50
Dividend/Share
₹22.50
Ex DateEx Date
Oct 17, 2023
Cash Dividend
Ex DateEx DateMar 24, 2023
Interim
Interim | Div/Share: ₹21.00
Dividend/Share
₹21.00
Ex DateEx Date
Mar 24, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹10.50
Dividend/Share
₹10.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Interim
Interim | Div/Share: ₹10.50
Dividend/Share
₹10.50
Ex DateEx Date
Nov 22, 2021
ALIVUS Stock News & Opinions
Articles & Videos
Corporate
Alivus Life Sciences to hold board meeting
Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Alivus Life Sciences allots 92,096 equity shares under ESOS
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-. Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales641.84572.80 12 OPM %29.6530.13 - PBDT200.31173.87 15 PBT185.15160.69 15 NP136.96118.77 15 Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY. On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, 'The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Alivus Life Sciences Ltd leads gainers in 'A' group
Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.Alivus Life Sciences Ltd surged 6.82% to Rs 1178.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 11436 shares were traded on the counter so far as against the average daily volumes of 5071 shares in the past one month. Avantel Ltd spiked 6.10% to Rs 143.6. The stock was the second biggest gainer in 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 1.35 lakh shares in the past one month. Sunteck Realty Ltd soared 5.43% to Rs 517.7. The stock was the third biggest gainer in 'A' group. On the BSE, 1.38 lakh shares were traded on the counter so far as against the average daily volumes of 12899 shares in the past one month. Spandana Sphoorty Financial Ltd advanced 4.99% to Rs 366.95. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 1.94 lakh shares in the past one month. Jai Corp Ltd gained 4.22% to Rs 157. The stock was the fifth biggest gainer in 'A' group. On the BSE, 71599 shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Glenmark Life Sciences renamed as Alivus Life Sciences
Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals. The change is reflective of the company's evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey. The official website is now alivus.com. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Glenmark Life Sciences declare Quarterly Result
Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Glenmark Life Sciences renamed Alivus Life Sciences
Glenmark Life Sciences has been renamed Alivus Life Sciences with effect from 17 December 2024. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Glenmark Life Sciences standalone net profit declines 19.72% in the September 2024 quarter
Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ended September 2024 as against Rs 118.74 crore during the previous quarter ended September 2023. Sales declined 14.86% to Rs 506.88 crore in the quarter ended September 2024 as against Rs 595.36 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales506.88595.36 -15 OPM %26.5128.07 - PBDT142.55172.06 -17 PBT127.46158.93 -20 NP95.32118.74 -20 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Glenmark Life Sciences announces board meeting date
Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20.95%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.4% to 0.6%
Over the last 5 years, net income has grown at a yearly rate of 19.21%, vs industry avg of 15.28%